Indo-Bangla Pharmaceuticals Limited (DSE:IBP)

Bangladesh flag Bangladesh · Delayed Price · Currency is BDT
12.40
+0.10 (0.81%)
At close: Feb 10, 2026
Market Cap1.44B +24.0%
Revenue (ttm)198.02M +66.3%
Net Income-32.60M
EPS-0.27
Shares Out116.21M
PE Ration/a
Forward PEn/a
Dividend0.02 (0.12%)
Ex-Dividend DateDec 8, 2025
Volume1,085,799
Average Volume826,444
Open12.40
Previous Close12.30
Day's Range12.30 - 12.50
52-Week Range8.50 - 15.60
Beta0.09
RSI58.30
Earnings DateJan 15, 2026

About DSE:IBP

Indo-Bangla Pharmaceuticals Limited engages in the manufacture and sale of various medicines, medical preparations drugs, and chemicals in Bangladesh and internationally. The company’s principal products include Omeprazole, Esomeprazole, Dexamethasone, Domperidone, Metronidazole, Montelukast, Paracetamol, Sildenafil Citrate, and several other formulations. It markets its products in various forms, such as tablets, capsules. Indo-Bangla Pharmaceuticals Limited was founded in 1954 and is based in Dhaka, Bangladesh. [Read more]

Industry Pharmaceutical Preparations
Founded 1954
Employees 127
Stock Exchange Dhaka Stock Exchange
Ticker Symbol IBP
Full Company Profile

Financial Performance

In fiscal year 2025, DSE:IBP's revenue was 184.18 million, an increase of 4.27% compared to the previous year's 176.64 million. Losses were -36.83 million, -10.12% less than in 2024.

Financial Statements